Sign In
Buy FLGT
$16.55
-3.66 (-18.11%)
At Close: Jul 31, 2026
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
08:23am, Friday, 31'st Jul 2026
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics Q2 Earnings Call Highlights
07:04pm, Thursday, 30'th Jul 2026
Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Ba
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
07:00pm, Thursday, 30'th Jul 2026
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to earnings of $0.07 per share a year ago.
Fulgent Reports Second Quarter 2026 Financial Results
04:05pm, Thursday, 30'th Jul 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent Genetics: Strong Moves By Management Keep Me Bullish
05:36pm, Monday, 13'th Jul 2026
Fulgent Genetics remains a long-term play, supported by a strong balance sheet and disciplined capital allocation. Recent opportunistic share repurchases at $15.42/share and insider buying highlight m
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
04:05pm, Thursday, 09'th Jul 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
Fulgent Presents Updated FID-007 Data at ASCO 2026
07:00pm, Monday, 01'st Jun 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic developme
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). The investigation focuses on Fulgent
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
07:00am, Monday, 04'th May 2026
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
12:21pm, Friday, 01'st May 2026
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
09:10am, Friday, 01'st May 2026
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.04 per share a year ago.
Fulgent Reports First Quarter 2026 Financial Results
07:00am, Friday, 01'st May 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
